ABPI Brexit preparations include ensuring continued UK participation in EU regulatory and medicines safety processes.
News
Gov’t moves to curb HRT shortages
Plans will support existing efforts to reduce medicine shortages to protect NHS patients.
NICE draft ‘no’ for Roche’s Tecentriq
The committee felt that comparison to existing treatments for the condition was “unreliable and lacked validity”.
2018 winner offers insight into the Medical & Scientific Excellence Awards
Deborah Clarke of Boehringer Ingelheim reveals her experience with the competition and the important role it plays within the industry.
Novartis, Microsoft collab to ‘transform medicine’ with AI
The companies have committed to a multi-year research and development effort which will focus on AI empowerment and AI exploration.
Tickets available for the 2019 Sales Awards gala dinner and ceremony
This year’s awards ceremony will be taking place at the Chelsea Harbour Hotel on the 14th November.
Tecentriq combo proves effective in bladder cancer
The drug improved progression-free survival to 8.2 months from 6.3 months.
Zejula successful in advanced ovarian cancer
GlaxoSmithKline presented the results at the ESMO Congress.
Novartis announces positive asthma results
Marketing applications for the treatments are currently being reviewed by the EMA.
Survey reveals women with cancer feel ‘stigmatised’
The report found that there is still significant “room for improvement to promote understanding of all cancers and their risk factors.”
Continued success for Lynparza in ovarian cancer
The drug improved progression-free survival time to a median of 22.1 months, compared to 16.6 months.
Lynparza bags positive prostate cancer results
The drug more than doubled median radiographic progression-free survival.
Invokana bags FDA approval
The treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes.
Report shows no-deal Brexit is still a “highly uncertain environment”
The National Audit Office report states that despite the extensive preparations, there still remains a “significant amount to do before 31 October.”
NICE guidance could avert 1,000+ neonatal admissions
The guidance could lead to as many as 634 fewer emergency caesarean sections and 1,308 fewer neonatal admissions in England, per year.
